Share Capital Analysis As of May 30, 2023, MD&AThe company did recently announce they would be activley seeking partners 2023 - 2024. Lots of money tied up in low priced warrants. A head scratcher for sure why we can not get the sp up far enough to access warrant cash.
Share Capital Analysis As of May 30, 2023, the share capital of the Company consisted of 216,502,675 common shares. Each common share entitles the holder to one vote per share. As of May 30, 2023, there were 18,150,000 options outstanding, of which 10,280,000 were vested and exercisable into an equivalent number of the Company’s common shares. As of May 30, 2023, there were 75,812,650 warrants outstanding. Each whole warrant entitles the holder thereof to purchase one additional common share. The warrants are exercisable as follows: 3,157,059 at a price of $0.50 until October 3, 2023, 4,095,157 at a price of $0.50 until January 9, 2023, 57,499,000 at a price of $0.35 until August 22, 2024, 10,058,734 at a price of $0.35 until September 22, 2024 and 1,002,700 at a price of $0.35 until November 17, 2024. As of May 30, 2023, there were 2,023,077 broker compensation units that were issued in connection with the August 22, 2019 public offering. Each broker compensation unit entitles the holder thereof to acquire one common share and one common share purchase warrant at a price of $0.35 per unit until August 22, 2024. Segmented Information For management purposes, the Company is organized into two separate reportable operating divisions; the Anti-Cancer Therapy (“ACT”) division and the Cool Laser Therapy (“CLT”) division. The ACT division is responsible for the research and development of PDCs primarily for the treatment of cancer with assistance from the CLT division to develop medical lasers to activate them. The CLT division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes CLT systems to healthcare practitioners predominantly for the healing of pain.